UK Approves Groundbreaking CRISPR-Based Gene Therapy For Sickle Cell Disease And Thalassemia
Gene therapy takes a giant leap forward as Exa-cel becomes the world’s first CRISPR/Cas9 gene-edited therapy approved to treat sickle cell disease and thalassemia.
Gene therapy takes a giant leap forward as Exa-cel becomes the world’s first CRISPR/Cas9 gene-edited therapy approved to treat sickle cell disease and thalassemia.
What's Your Reaction?
